Hypophosphatemia in patients with autosomal dominant polycystic kidney disease: The role of fibroblast growth factor 23 or loss of sodium/phosphate cotransporter

Kidney International

Volumn 80, Issue 5, 2011, Pages 554-555

  Park, Se Jin ^a   Kim, Ji Hong ^a   Ha, Tae Sun ^b   Shin, Jae Il ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Chungbuk National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; OXYGENASE; PHOSPHATE; SODIUM PHOSPHATE COTRANSPORTER 2; FIBROBLAST GROWTH FACTOR;

CELL DAMAGE; CELL PROLIFERATION; DISEASE ASSOCIATION; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HYPOPHOSPHATEMIA; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EPITHELIUM; LETTER; NEPHRON; PATHOGENESIS; PHOSPHATE EXCRETION; PHOSPHATURIA; PRIORITY JOURNAL; URINARY EXCRETION; BLOOD; FEMALE; KIDNEY; MALE; METABOLISM; NOTE;

FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY; MALE; PHOSPHATES; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

EID: 84862997281     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.203     Document Type: Letter

References (4)

1. Klawansky S, Komaroff E, Cavanaugh Jr PF et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 2003; 14: 570-576. (Pubitemid 36975556)
2. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822. (Pubitemid 46698462)
3. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007; 357: nihpa40967.
4. Woo KT, Chan CM. KDIGO clinical practice guidelines for bisphosphonate treatment in chronic kidney disease. Kidney Int 2011; 80: 553-554.